<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5883">
  <stage>Registered</stage>
  <submitdate>13/05/2016</submitdate>
  <approvaldate>13/05/2016</approvaldate>
  <nctid>NCT02774616</nctid>
  <trial_identification>
    <studytitle>Master Study of the Ilivia ICD Family and the Plexa ICD Lead</studytitle>
    <scientifictitle>BIO|MASTER.Ilivia Family / Plexa</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TA111</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Tachyarrhythmia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Ilivia ICD Family
Treatment: devices - Plexa ICD lead

Other: Ilivia ICD Family - Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting

Other: Plexa ICD lead - Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting


Treatment: devices: Ilivia ICD Family
pre-defined device programming, measurements and follow-up schedule

Treatment: devices: Plexa ICD lead
predefined follow-up schedule

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ilivia Family related SADE-free rate through 3 months</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Plexa related SADE-free rate through 3 months</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with successful fast ventricular arrhythmia conversion by ATP one-shot at 6-month follow-up</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of appropriate right ventricular sensing at 3-month follow-up</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of appropriate right ventricular pacing at 3-month follow-up</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Standard indication for ICD or CRT-D therapy according to clinical practice

          -  De novo implantation or upgrade/exchange (group A only) from existing ICD, CRT-D or
             pacemaker implant

          -  Patient is able to understand the nature of the clinical investigation and provides
             written informed consent

          -  Patient is able and willing to complete all routine study visits at the
             investigational site

          -  Patient accepts Home Monitoring concept

          -  Age = 18 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Contraindication to ICD or CRT-D therapy, respectively

          -  For CRT-D patients in group A only: physician not willing to activate MultiPole Pacing
             in the patient

          -  Cardiac surgical procedure planned within 6 months after implantation (including also
             interventional procedures like ablation, valve replacement etc.). Procedures to occur
             during or prior to implantation are not exclusionary.

          -  Expected to receive heart transplant or ventricular assist device within 6 months

          -  Life expectancy less than 6 months

          -  Participation in any other interventional clinical investigation

          -  Pregnant or breastfeeding at time of enrollment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>292</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Nambour General Hospital - Nambour</hospital>
    <postcode> - Liverpool</postcode>
    <postcode> - Nambour</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>St. Pölten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Langensalza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Oeynhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Brandenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kaiserslautern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Singen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Sebastian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Luzern</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biotronik SE &amp; Co. KG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Post-Market Clinical Follow-up of the new Ilivia ICD Family and the new Plexa right
      ventricular lead to fulfill requirements by the notified body and to support regulatory
      approval outside of the CE region</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02774616</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christian Sticherling, Prof. Dr.</name>
      <address>Universitätsspital Basel</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>